effect of Dexmedetomidine, Neostigmin and Ketamin on fibrosis of laminectomy

Comparison between the effect of Dexmedetomidine, Neostigmine, and Ketamine coadministered with bupivacaine 0.5% in epidural administration on decreasing of fibrosis after laminectomy

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20181212041947N1

Enrollment

Registered

2020-08-24

Start date

2020-08-05

Completion date

Unknown

Last updated

2020-09-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Laminectomy surgery. Postlaminectomy syndrome, not elsewhere classified

Interventions

Intervention 1: Intervention group1:We inject 0.3 milligram in kilogram of ketamine (volume of which is increased to 3 millilitre), is added to 75 mg of Marcaine 0.25 percent. Intervention 2: Interv

Eligibility

Sex/Gender

All

Age

25 Years to 70 Years

Inclusion criteria

Inclusion criteria: All patients candidate for Laminectomy surgery All patients with informed consent to participate in the trial All patients with range of age between 25 to 70 years old All patients with Anesthetic ASA class I or II

Exclusion criteria

Exclusion criteria: All patients out of range of age between 25 to 70 years old All patients who were not candidate for Laminectomy surgery All patients with Sensitivity to Dexmedetomidine, Neostigmin and Ketamin All patients with ASA class more than II (III, IV) All female patients in pregnancy or lactation period All patients with uncontrolled psychological disorders

Design outcomes

Primary

Measure	Time frame
Mean value of thickness of fibrosis due to laminectomy. Timepoint: 3 months after surgery. Method of measurement: Milimeters.;Pain. Timepoint: 2, 6, 12 hours after surgery. Method of measurement: Visual analog scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Ali Nazemi Rafie

Arak University of Medical Sciences

z.khademi@arakmu.ac.ir+98 86 3313 6055

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026